ProCE Banner Activity

Phase I/II Trial of BTK Inhibitor Rilzabrutinib (PRN1008) for Heavily Pretreated Patients With Immune Thrombocytopenia

Slideset Download
Conference Coverage
Rilzabrutinib was well tolerated and associated with rapid, durable responses in heavily pretreated adults with immune thrombocytopenia.

Released: December 16, 2020

Expiration: December 15, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology